Biosimilar Newsletter Archive

11. 11.03.21 -- BridgeBio's Approach To Gene Therapy, The CDMO Capacity Crunch And More 11/3/2021
    11/03/21 Biosimilar Development Newsletter
12. 10.28.21 -- Is The FDA About To Reclassify Your Drug Product As A Device? 10/28/2021
    10/28/21 Biosimilar Development Newsletter
13. 10.26.21 -- Flexible From The Start | A Tailored Approach To Cell Line Development 10/26/2021

    10/26/21 Biosimilar Development Newsletter

14. 10.25.21 -- Better Bioprocessing Efficiency Through Centralized Orchestration 10/25/2021
    10/25/21 Biosimilar Development Newsletter
15. 10.22.21 -- Base Your Cryogenic Cold Chain Processes On Cellular Biology, Physics, And Your Patients' Needs 10/22/2021
    10/22/21 Biosimilar Development Newsletter
16. 10.21.21 -- Data Integrity: 9 Pitfalls To Avoid 10/21/2021
    10/21/21 Biosimilar Development Newsletter
17. 10.14.21 -- Building More Resilient API Supply Chains 10/14/2021

    10/14/21 Biosimilar Development Newsletter

18. 10.14.21 -- FDA Accepts Polpharma's, Coherus' Respective Lucentis BLAs 10/14/2021
    10/14/21 Biosimilar Development Newsletter
19. 10.08.21 -- 5 Strategies For Your Future Success 10/8/2021

    10/08/21 Biosimilar Development Newsletter

20. 10.07.21 -- FDA's Final Rule On Intended Use Leaves Something To Be Desired 10/7/2021
    10/07/21 Biosimilar Development Newsletter